Search PubMed⌕ Search

PubMed · 15647984

[CTG: microfluctuation].

Abstract

OBJECTIVE: Microfluctuation (MF) of fetal heart rate (FHR) is regarded as the most sensitive parameter for diagnosing the condition of the fetus. The MF can only be crudely quantified with the naked eye. Therefore the following questions arise: 1) How can MF be exactly measured numerically? 2) What interrelationships are there between the MF determined electronically, the basal FHR, the oscillation amplitude (OA) of the FHR and the beat-to-beat variability (beat-to-beat var.) 3) What are the effects of hypoxia and acidosis on these index parameters? METHODS: 387 intrapartal FHR tracings were registered directly (F-ECG) with the cardiotocograph (HP instruments) via an RS422 interface and stored on diskette. The data were processed further with a computer program we developed ourselves (MATLAB, the MathWorks Inc., USA). The parameters of the fetal acid-base balance were measured in the blood of the umbilical artery (UA) and umbilical vein (UV) with instruments from Radiometer, Copenhagen (ABL 500, ABL 5) and stored off-line with a selection of clinical data and processed further on a laptop (HP, Omnibook XE 3). The fluctuation of the basal FHR was determined on the basis of the following four parameters: the number of high and low points (extrema) per minute (EXT),the mean beat-to-beat variability per minute and the OA (bpm). In order to correlate the MF of the basal FHR with the parameters of the fetal acid-base balance, only the last 30 CTG minutes ante-partum of each tracing were included. All decelerations and optionally in addition all accelerations were electronically deleted from the FHR curve. RESULTS: Basic statistical values and the distribution of the four index parameters in 5486 minutes of basal FHR were studied: the median of EXT is at 59 and the mean value at 58.9 +/- 13.9 extrema/min. The distribution is normal. The median frequency amounts to 138 bpm, the median OA to 22.2 bpm and the median beat-to-beat variability to 161.7 bpm, respectively. The mean pH value in UA blood was 7.262 +/- 0.064. The acidotic risk (pH, UA < 7.100) reached 1.3 %. There were no pH values below 7.0. With increasing basal FHR, EXT increases highly significantly (r = 0.468, P << 0.0000). EXT decreases highly significantly (r = -0.432, P << 0.0000) with increasing OA. The mean basal frequency shows the best correlation with the base excess in UA blood (r = -0.263, P << 0.0000). Beat-to-beat variability and EXT alone correlate poorly with the actual, pH and BE values (UA). Multiplication of the index parameters leads to an increase of the correlation coefficients when compared with their single values. CONCLUSION: With increasing hypoxia and acidosis the four index parameters do show a complex pattern which is characterized by tachycardia, increase of EXT and opening of the OA. A loss of EXT and a reduction of OA seems to be the result of already severe acidosis (pH, UA < 7.000). Using the four parameters of basal FHR alone, there is no possibility to evaluate fetal jeopardization. Numerical combination (e. g., multiplication) of some index parameters ameliorates their prognostic power and should be used in future online scoring procedures.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

V M Roemer. 2004. [CTG: microfluctuation].. https://doi.org/10.1055/s-2004-835867

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Ras triggers acidosis-induced activation of the extracellular-signal-regulated kinase pathway in cardiac myocytes.

In cardiac myocytes, sustained (3 min) intracellular acidosis activates the ERK1/2 (extracellular-signal-regulated kinase 1/2) pathway and, through this pathway, increases sarcolemmal NHE (Na+/H+ exchanger) activity [Haworth, McCann, Snabaitis, Roberts and Avkiran (2003) J. Biol. Chem. 278, 31676-31684]. In the present study, we aimed to determine the time-dependence, pH-dependence and upstream signalling mechanisms of acidosis-induced ERK1/2 activation in ARVM (adult rat ventricular myocytes). Cultured ARVM were subjected to intracellular acidosis for up to 20 min by exposure to NH4Cl, followed by washout with a bicarbonate-free Tyrode solution containing the NHE1 inhibitor cariporide. After the desired duration of intracellular acidosis, the phosphorylation status of ERK1/2 and its downstream effector p90(RSK) (90 kDa ribosomal S6 kinase) were determined by Western blotting. This revealed a time-dependent transient phosphorylation of both ERK1/2 and p90(RSK) by intracellular acidosis (intracellular pH approximately 6.6), with maximum activation occurring at 3 min and a return to basal levels by 20 min. When the degree of intracellular acidosis was varied from approximately 6.8 to approximately 6.5, maximum ERK1/2 phosphorylation was observed at an intracellular pH of 6.64. Inhibition of MEK1/2 [MAPK (mitogen-activated protein kinase)/ERK kinase 1/2) by pre-treatment of ARVM with U0126 or adenoviral expression of dominant-negative D208A-MEK1 protein prevented the phosphorylation of ERK1/2 by sustained intracellular acidosis, as did inhibition of Raf-1 with GW 5074 or ZM 336372. Interference with Ras signalling by the adenoviral expression of dominant-negative N17-Ras protein or with FPT III (farnesyl protein transferase inhibitor III) also prevented acidosis-induced ERK1/2 phosphorylation, whereas inhibiting G-protein signalling [by adenoviral expression of RGS4 or Lsc, the RGS domain of p115 RhoGEF (guanine nucleotide-exchange factor)] or protein kinase C (with bisindolylmaleimide I) had no effect. Our data show that, in ARVM, sustained intracellular acidosis activates ERK1/2 through proximal activation of the classical Ras/Raf/MEK pathway.

Acidosis↗

Vardenafil increases coronary flow response to hypercapnic acidosis in isolated guinea pig heart.

The hypothesis was tested that vardenafil, a PDE5 inhibitor, specifically enhances coronary vasodilation during acidosis. In isolated constant pressure perfused guinea pig hearts, infusion of vardenafil (<or= 1 microM) increased coronary flow concentration-dependently 34 % above baseline. In parallel, cGMP release increased (0.44 +/- 0.094 vs. 0.14 +/- 0.017 pmol/min x g at 0.5 microM vardenafil vs. baseline). Flow increases occurred in the absence of changes in heart function (LVP, heart rate, dP/dt(max), heart rate - pressure product). Infusion of the NO synthase blocker L-NMMA (100 microM) caused a rightward shift of the dose-response curve of vardenafil. To test whether vardenafil treatment may enhance metabolic coronary vasodilation, arterial pCO(2) was raised from 38 to 61 mmHg, which resulted in a steady state flow increase of 18.8 +/- 4.5%. Infusion of vardenafil, given at a threshold flow enhancing concentration, doubled the coronary flow response during hypercapnic acidosis to 38.4 +/- 4.2 % (p=0.004). This flow amplification during acidosis was not shared by the K(ATP) channel opener cromakalim, indicating a specific effect of vardenafil on flow control during myocardial acidosis. We conclude that vardenafil specifically relaxes coronary resistance vessels through NO/cGMP-dependent pathways and increases the coronary flow response toward hypercapnic acidosis. This finding further supports the importance of the NO-cGMP axis in mediation of this flow response.

Acidosis↗